Literature DB >> 14706257

Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung.

Jeffrey O-H Sham1, Yu Zhang, Warren H Finlay, Wilson H Roa, Raimar Löbenberg.   

Abstract

Spray-drying is a common practice of powder preparation for a wide range of drugs. Spray-dried powders can be used to deliver particles to the lungs via a dry powder inhaler (DPI). The present study investigated the feasibility of developing a platform for aerosol delivery of nanoparticles. Lactose was used as the excipient and spray-dried with two different types of nanoparticles: gelatin and polybutylcyanoacrylate nanoparticles. Results showed that some carrier particles were hollow while others had a continuous matrix. Gelatin nanoparticles were incorporated throughout the matrix and sometimes accumulated at one end of the lactose. Polycyanoacrylate nanoparticles mostly clustered in different spots within the lactose carriers. The mean sizes of both nanoparticle types were characterized at two different times: before they were spray-dried and after they were redissolved from the spray-dried powders. Both nanoparticle types remained in the nano-range size after spray-drying. The mean nanoparticle sizes were increased by approximately 30% after spray-drying, though this increase was statistically significant only for the gelatin nanoparticles. Dispersion of the powder with an in-house passive dry powder inhaler and subsequent cascade impaction measurements showed that incorporation of the nanoparticles did not affect the fine particle fraction (FPF) or mass median aerodynamic diameter (MMAD) of the powders. FPF was approximately 40% while MMAD was 3.0+/-0.2 microm, indicating the present formulations yield aerosols of a suitable particle size for efficient lung delivery of nanoparticles. The present work demonstrates that nanoparticles can be delivered to the lungs via carrier particles that dissolve after coming in contact with the aqueous environment of the lung epithelium. This opens the way for new drug-targeting strategies using nanoparticles for pulmonary delivery of drugs and diagnostics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706257     DOI: 10.1016/j.ijpharm.2003.09.041

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  36 in total

1.  Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation.

Authors:  M H D Kamal Al-Hallak; Shirzad Azarmi; Chris Sun; Patrick Lai; Elmar J Prenner; Wilson H Roa; Raimar Löbenberg
Journal:  AAPS J       Date:  2010-04-20       Impact factor: 4.009

2.  Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.

Authors:  Yan-Zhen Li; Xun Sun; Tao Gong; Jie Liu; Jiao Zuo; Zhi-Rong Zhang
Journal:  Pharm Res       Date:  2010-07-13       Impact factor: 4.200

Review 3.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Authors:  Svetlana Gelperina; Kevin Kisich; Michael D Iseman; Leonid Heifets
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 4.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 5.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 6.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

Review 7.  Nanomaterial Drug Products: Manufacturing and Analytical Perspectives.

Authors:  Christie M Sayes; Grace V Aquino; Anthony J Hickey
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

8.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

9.  Self-Assembled Nanospheres for Encapsulation and Aerosolization of Rifampicin.

Authors:  Aline A Ishikawa; Jesus V Salazar; Magaly Salinas; Cristiane M Gaitani; Timothy Nurkiewicz; George R Negrete; Carlos D Garcia
Journal:  RSC Adv       Date:  2016-01-26       Impact factor: 3.361

Review 10.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.